- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Redwood City Today
By the People, for the People
Guardant Health Highlights Growth Plans for Cancer Tests at Leerink Conference
Company touts new Quest partnership, Guardant360 expansion, and upcoming regulatory milestones
Mar. 17, 2026 at 8:03am
Got story updates? Submit your updates here. ›
Guardant Health executives discussed the company's growth initiatives for its cancer screening and therapy selection tests, including a new partnership with Quest Diagnostics to expand access to its Shield colorectal cancer screening test, continued adoption of the Guardant360 liquid biopsy, and upcoming regulatory and reimbursement milestones.
Why it matters
As a leader in precision oncology diagnostics, Guardant Health's performance and product pipeline are closely watched by the healthcare industry. The company's ability to drive adoption of its cancer tests and navigate the regulatory landscape will be key to its long-term success.
The details
Guardant highlighted plans to leverage its Quest partnership to make Shield more accessible through electronic medical record integration and co-promotion. The company also touted growth drivers for Guardant360, including broader liquid biopsy adoption and increased repeat testing. Executives discussed the potential impact of an anticipated FDA approval and ADLT reimbursement for Guardant360, as well as commercialization strategies for the Shield test including direct-to-consumer marketing and sales force expansion.
- Guardant remains on track for FDA approval of Guardant360 in the second half of 2026.
- An ADLT reprice for Guardant360 would likely be finalized in the first part of 2027.
The players
Guardant Health
A precision oncology company specializing in blood-based cancer diagnostics, founded in 2012 and headquartered in Redwood City, California.
Quest Diagnostics
A leading provider of diagnostic information services, with which Guardant has partnered to expand access to the Shield colorectal cancer screening test.
AmirAli Talasaz
Co-CEO of Guardant Health.
Helmy Eltoukhy
Co-CEO of Guardant Health.
Mike Bell
CFO of Guardant Health.
What they’re saying
“We must not let individuals continue to damage private property in San Francisco.”
— Robert Jenkins, San Francisco resident (San Francisco Chronicle)
“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”
— Gordon Edgar, grocery employee (Instagram)
What’s next
The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.
The takeaway
This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.
